Literature DB >> 12707324

Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells.

Pedro L Vieira1, Heleen C Heystek, Jan Wormmeester, Eddy A Wierenga, Martien L Kapsenberg.   

Abstract

Glatiramer acetate (GA; copolymer-1, Copaxone) suppresses the induction of experimental autoimmune encephalomyelitis and reduces the relapse frequency in relapsing-remitting multiple sclerosis. Although it has become clear that GA induces protective degenerate Th2/IL-10 responses, its precise mode of action remains elusive. Because the cytokine profile of Th cells is often regulated by dendritic cells (DC), we studied the modulatory effects of GA on the T cell regulatory function of human DC. This study shows the novel selective inhibitory effect of GA on the production of DC-derived inflammatory mediators without affecting DC maturation or DC immunostimulatory potential. DC exposed to GA have an impaired capacity to secrete the major Th1 polarizing factor IL-12p70 in response to LPS and CD40 ligand triggering. DC exposed to GA induce effector IL-4-secreting Th2 cells and enhanced levels of the anti-inflammatory cytokine IL-10. The anti-inflammatory effect of GA is mediated via DC as GA does not affect the polarization patterns of naive Th cells activated in an APC-free system. Together, these results reveal that APC are essential for the GA-mediated shift in the Th cell profiles and indicate that DC are a prime target for the immunomodulatory effects of GA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12707324     DOI: 10.4049/jimmunol.170.9.4483

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  64 in total

Review 1.  Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.

Authors:  Reinhard Hohlfeld; Hartmut Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

2.  Glatiramer acetate triggers PI3Kδ/Akt and MEK/ERK pathways to induce IL-1 receptor antagonist in human monocytes.

Authors:  Rakel Carpintero; Karim J Brandt; Lyssia Gruaz; Nicolas Molnarfi; Patrice H Lalive; Danielle Burger
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-27       Impact factor: 11.205

3.  Multimerized T cell epitopes protect from experimental autoimmune diabetes by inducing dominant tolerance.

Authors:  Eliane Piaggio; Lennart T Mars; Cécile Cassan; Julie Cabarrocas; Maria Hofstätter; Sabine Desbois; Emilie Bergereau; Olaf Rötzschke; Kirsten Falk; Roland S Liblau
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-16       Impact factor: 11.205

4.  Glatiramer acetate modulates TNF-α and IL-10 secretion in microglia and promotes their phagocytic activity.

Authors:  Refik Pul; Darius Moharregh-Khiabani; Jelena Škuljec; Thomas Skripuletz; Niklas Garde; Elke Verena Voss; Martin Stangel
Journal:  J Neuroimmune Pharmacol       Date:  2010-11-03       Impact factor: 4.147

5.  Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis.

Authors:  A Sanna; M L Fois; G Arru; Y-M Huang; H Link; M Pugliatti; G Rosati; S Sotgiu
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

6.  Amino acid copolymer-specific IL-10-secreting regulatory T cells that ameliorate autoimmune diseases in mice.

Authors:  Joel N H Stern; Derin B Keskin; Hong Zhang; Huijuan Lv; Zenichiro Kato; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-24       Impact factor: 11.205

Review 7.  The role of B cells in the immunopathogenesis of multiple sclerosis.

Authors:  Tohid Gharibi; Zohreh Babaloo; Arezoo Hosseini; Faroogh Marofi; Abbas Ebrahimi-Kalan; Saeed Jahandideh; Behzad Baradaran
Journal:  Immunology       Date:  2020-05-10       Impact factor: 7.397

8.  P-glycoprotein acts as an immunomodulator during neuroinflammation.

Authors:  Gijs Kooij; Ronald Backer; Jasper J Koning; Arie Reijerkerk; Jack van Horssen; Susanne M A van der Pol; Joost Drexhage; Alfred Schinkel; Christine D Dijkstra; Joke M M den Haan; Teunis B H Geijtenbeek; Helga E de Vries
Journal:  PLoS One       Date:  2009-12-08       Impact factor: 3.240

Review 9.  Remyelination therapy for multiple sclerosis.

Authors:  Michael B Keough; V Wee Yong
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

Review 10.  Dendritic cells as therapeutic targets in neuroinflammation.

Authors:  Felix Luessi; Frauke Zipp; Esther Witsch
Journal:  Cell Mol Life Sci       Date:  2016-03-12       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.